Physician profile
Karolynn Echols
NPI 1992716419
$38,052.62
in general payments reported to CMS, 2019-2025
15 companies · $9,621 in 2025
The $9,621 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,148 · 2020: $1,036 · 2021: $1,319 · 2022: $9,239 · 2023: $3,155 · 2024: $4,535 · 2025: $9,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $5,694 · Consulting Fee: $1,200 · Travel and Lodging: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,000.00 |
| Food and Beverage | $5,693.74 |
| Consulting Fee | $1,200.00 |
| Travel and Lodging | $416.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18,780.03 | 2021-2025 | Interstim, Intellis Adaptivestim, Altaviva |
| Coloplast Corp | $8,289.85 | 2019-2025 | Saffron |
| Abbvie INC. | $6,770.02 | 2022-2025 | Botox |
| Medtronic USA, INC. | $1,890.32 | 2019-2020 | |
| Applied Medical Resources Corporation | $753.84 | 2022-2023 | Gelpoint V-Path |
| Arteriocyte Medical Systems, INC. | $486.73 | 2019-2023 | Magellan |
| Allergan, INC. | $360.91 | 2019-2021 | |
| Femselect INC. | $346.20 | 2023 | Enplace |
| Astellas Pharma US INC | $100.15 | 2025 | Veozah |
| Covidien LP | $76.79 | 2019 | |
| Boston Scientific Corporation | $65.48 | 2019 | |
| Medtronic Vascular, INC. | $53.44 | 2019 | |
| Sumitomo Pharma America, INC. | $52.37 | 2025 | Gemtesa |
| Millicent US INC | $13.66 | 2025 | Intrarosa |
| Mission Pharmacal Company | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karolynn Echols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.